Molecure Future Growth

Future criteria checks 2/6

Molecure is forecast to grow earnings and revenue by 11.2% and 48.4% per annum respectively. EPS is expected to decline by 2.8% per annum. Return on equity is forecast to be -56.6% in 3 years.

Key information

11.2%

Earnings growth rate

-2.8%

EPS growth rate

Pharmaceuticals earnings growth	15.8%
Revenue growth rate	48.4%
Future return on equity	-56.6%
Analyst coverage	Low
Last updated	05 Nov 2024

Recent future growth updates

Recent updates

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Feb 24

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

Jan 02

Earnings and Revenue Growth Forecasts

WSE:MOC - Analysts future estimates and past financials data (PLN Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	40	-12	N/A	5	2
12/31/2025	63	-17	N/A	16	2
12/31/2024	3	-28	N/A	-25	2
9/30/2024	2	-31	-61	-33	N/A
6/30/2024	2	-30	-67	-29	N/A
3/31/2024	2	-29	-55	-16	N/A
12/31/2023	4	-28	-57	-23	N/A
9/30/2023	9	-45	-53	-40	N/A
6/30/2023	8	-42	-41	-34	N/A
3/31/2023	8	-39	-48	-39	N/A
12/31/2022	8	-36	-44	-34	N/A
9/30/2022	2	-16	-36	-8	N/A
6/30/2022	2	-16	-38	-14	N/A
3/31/2022	2	-15	-37	-15	N/A
12/31/2021	1	-14	-32	-13	N/A
9/30/2021	124	63	63	47	N/A
6/30/2021	124	64	62	47	N/A
3/31/2021	125	67	67	56	N/A
12/31/2020	125	68	66	57	N/A
9/30/2020	2	-3	-31	-2	N/A
6/30/2020	2	-3	-32	-2	N/A
3/31/2020	2	-4	-38	-6	N/A
12/31/2019	2	-4	-42	-7	N/A
9/30/2019	2	-5	-43	-4	N/A
6/30/2019	2	-5	-41	-6	N/A
3/31/2019	1	-5	-36	-4	N/A
12/31/2018	1	-4	-32	-5	N/A
9/30/2018	1	-4	-28	-5	N/A
6/30/2018	2	-4	N/A	-2	N/A
3/31/2018	2	-2	N/A	-2	N/A
12/31/2017	1	-2	N/A	-1	N/A
9/30/2017	1	-3	N/A	-5	N/A
6/30/2017	1	-3	N/A	-4	N/A
3/31/2017	1	-3	N/A	-3	N/A
12/31/2016	1	-2	N/A	-1	N/A
12/31/2015	1	-1	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MOC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MOC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MOC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MOC's revenue (48.4% per year) is forecast to grow faster than the Polish market (4% per year).

High Growth Revenue: MOC's revenue (48.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MOC is forecast to be unprofitable in 3 years.

Molecure Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased by 22% to zł23.25

No longer forecast to breakeven

Recent updates

New minor risk - Share price stability

New minor risk - Profitability

Price target decreased by 22% to zł23.25

Second quarter 2024 earnings released: zł0.46 loss per share (vs zł0.29 loss in 2Q 2023)

Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

New major risk - Revenue and earnings growth

New minor risk - Financial position

No longer forecast to breakeven

Molecure S.A. Receives Approval to Initiate A Phase II Clinical Trial (KITE) for OATD-01 for the Treatment of Pulmonary Sarcoidosis in Selected Countries of the European Union and Norway

Molecure S.A., Annual General Meeting, Jun 13, 2024

New minor risk - Financial data availability

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis

Molecure S.A. to Report Q3, 2024 Results on Oct 31, 2024

New major risk - Revenue and earnings growth

Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Third quarter 2023 earnings released: zł0.25 loss per share (vs zł0.16 loss in 3Q 2022)

Second quarter 2023 earnings released

New minor risk - Share price stability

New minor risk - Shareholder dilution

Molecure S.A. Receives Clearance from the U.S. Food and Drug Administration on its Investigational New Drug Application to Conduct Phase II Clinical Testing of OATD-01

Molecure S.A. announced that it has received PLN 49.968 million in funding

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Molecure S.A., Annual General Meeting, May 31, 2023

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Molecure S.A. to Report Q1, 2023 Results on Apr 28, 2023

Molecure S.A. Announces Management Changes

Molecure S.A. to Begin Clinical Development of Novel Dual Arginase Inhibitor Oatd-02 for the Treatment of Cancer After Gaining Permission to Conduct First Clinical Trial in Poland

Third quarter 2022 earnings released: zł0.16 loss per share (vs zł0.13 loss in 3Q 2021)

Second quarter 2022 earnings released: zł0.27 loss per share (vs zł0.20 loss in 2Q 2021)

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Molecure S.A., Annual General Meeting, Jun 30, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

OncoArendi Therapeutics S.A. Announces Board Appointments

OncoArendi Therapeutics S.A Appoints Samson Fung as Chief Medical Officer

OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Second quarter 2021 earnings released: zł0.21 loss per share (vs zł0.034 loss in 2Q 2020)

CEO & President of Management Board recently bought zł178k worth of stock

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

OncoArendi Therapeutics S.A. to Report Q2, 2021 Results on Sep 27, 2021

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

New 90-day high: zł57.80

OncoArendi Therapeutics SA and Galapagos Enter into Exclusive Collaboration on Chitinase Inhibitors in Fibrosis

Third quarter 2020 earnings released: zł0.06 loss per share

First half earnings released

New 90-day high - zł19.70

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies